Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of orelabrutinib versus placebo in primary progressive multiple sclerosis
MOH_2026-08-27_017016Phase 3Not yet recruiting
- Sponsor
- Zenas BioPharma
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Orelabrutinib with Placebo (2 arms). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on MOH_2026-08-27_017016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-27_017016.